Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6991 participants.
Also called NCT01897532
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 6,991 participants
- Registry
-
NCT01897532 -
2011-004148-23
-
- Other papers using this trial's data
- Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
- Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Germany, Hungary, Israel, Japan, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Russia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01897532. Randomized; double masking; primary purpose treatment. Start 2013-07-10 (actual); primary completion 2018-01-18 (actual). Results posted on 2019-01-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Linagliptin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01897532- Content hash
cfe1bd91fff8b2f93ab732d42007b5636494d73b1bc2686fda9089fe57c57842